Skip to main content
. 2019 Feb 7;10(4):607–623. doi: 10.1111/1759-7714.12971

Figure 7.

Figure 7

Forest plots of relative risk of immune‐related adverse events (AEs) associated with immune checkpoint inhibitors (ICIs) ± chemotherapy versus chemotherapy ± placebo in first‐line treatment of non‐small cell lung cancer (NSCLC) population. Chemo, chemotherapy; CI, confidence interval; Placbo, placebo.